Immune-related adverse events are associated with better event-free survival in a phase I/II clinical trial of durvalumab concomitant with neoadjuvant chemotherapy in early-stage triple-negative breast cancer
The development of irAE was associated with numerically improved pCR rates, lower RCB, and significantly higher EFS in patients treated with neoadjuvant immune checkpoint therapy plus chemotherapy.
Authors
- Lajos Pusztai (ORCID: https://orcid.org/0000-0001-9632-6686)
- Alejandro Ríos-Hoyo (ORCID: https://orcid.org/0000-0001-5344-9168)
- Kim Blenman (ORCID: https://orcid.org/0000-0001-6070-0728)
- Tony Noël
- Jiawei Dai (ORCID: https://orcid.org/0000-0003-3806-5160)
- T. Park
Institutions
- Universitat Pompeu Fabra (ES)
- Yale Cancer Center (US)
- Yale University (US)
Publication Details
- Journal
- ESMO Open
- Published
- 2025-03-18
- DOI
- https://doi.org/10.1016/j.esmoop.2025.104494
- Citations
- 6
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 6.27
Funders
- AstraZeneca
- Sociedad Española de Oncología Médica
- National Cancer Institute